Form 4: Arcus Biosciences CEO Terry Rosen Receives Stock and Option Grants

Arcus Biosciences CEO Terry Rosen was granted 165,000 restricted stock units and options to purchase 650,000 shares of common stock.

Summary

• Terry Rosen, CEO of Arcus Biosciences, received 165,000 restricted stock units on January 23, 2025.
• These restricted stock units will vest in four equal annual installments starting December 15, 2025, contingent on continued service.
• Rosen also received options to purchase 650,000 shares of common stock at an exercise price of $13.33.
• These options become exercisable in 48 equal monthly installments after January 1, 2025, also subject to continued service.
• Following these transactions, Rosen beneficially owns 2,534,360 shares of common stock.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices, which are generally viewed positively as they align management and shareholder interests. There are no negative aspects to the document.

Positives

• The grants of stock and options align the CEO's interests with those of the shareholders.
• The vesting schedules for both the stock units and options encourage long-term commitment from the CEO.

Risks

• The vesting of the stock units and options is contingent on the CEO's continued service, which could be a risk if he were to leave the company.
• The value of the options is dependent on the future performance of the company's stock price.

Future Outlook

The vesting of the stock units and options is contingent on the CEO's continued service, suggesting a focus on long-term performance and stability.

Industry Context

Stock and option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders and incentivizing long-term value creation.

Comparison to Industry Standards

• Stock option grants are a standard practice for executive compensation in the biotech industry, similar to companies like Gilead Sciences and Regeneron.
• The vesting schedule of four years for the restricted stock units is also typical, aligning with long-term value creation goals.
• The 48-month vesting schedule for the options is also a common practice to incentivize long-term performance.

Stakeholder Impact

• Shareholders may view the grants positively as they align the CEO's interests with the company's long-term success.
• Employees may see this as a sign of stability and commitment from the leadership.

Key Dates

Keywords

stock options, restricted stock units, executive compensation, insider trading, beneficial ownership, Arcus Biosciences, RCUS, Terry Rosen